DM199 Advances in Pregnancy and Stroke Trials | Business and Finance News

DiaMedica Therapeutics is accelerating its breakthrough drug DM199, now advancing in pivotal trials for fetal growth restriction, preeclampsia, and acute ischemic stroke—conditions with no current treatments. With enrollment complete in key cohorts and promising data guiding next steps, the company is poised to deliver critical insights by early 2027, including an interim analysis of its stroke trial. Backed by strong finances and preclinical momentum, DiaMedica is positioning itself to transform outcomes for high-risk pregnancies and stroke patients through targeted vascular biology. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7f2d26ae667c5233